<?xml version="1.0" encoding="UTF-8"?>
<p id="p0230">Xu et al. reported that of 55 of 62 confirmed COVID-19 patients in Zhejiang province received antiviral treatment. Twenty-one patients (34%) received lopinavir/ritonavir and interferon-α2b inhalation, 17 (28%) received arbidol and lopinavir/ritonavir, and 8 (13%) received interferon-α2b by inhalation.
 <xref rid="bib37" ref-type="bibr">
  <sup>37</sup>
 </xref> Chen et al. reported that 75 of 99 confirmed patients in Wuhan received antiviral treatment, including oseltamivir, ganciclovir, and lopinavir/ritonavir.
 <xref rid="bib38" ref-type="bibr">
  <sup>38</sup>
 </xref> The duration of antiviral treatment was 3-14 days.
 <xref rid="bib38" ref-type="bibr">
  <sup>38</sup>
 </xref> However, the results of a clinical trial of lopinavir/ritonavir in China showed no clear benefit beyond standard care in hospitalized adult patients with severe COVID-19.
 <xref rid="bib39" ref-type="bibr">
  <sup>39</sup>
 </xref> Remdesivir may have the greatest potential for the successful treatment of SARS-CoV-2, but efficacy and safety in COVID-19 need further evaluation.
 <xref rid="bib40" ref-type="bibr">
  <sup>40</sup>
 </xref>
 <sup>,</sup>
 <xref rid="bib41" ref-type="bibr">
  <sup>41</sup>
 </xref> Remdesivir has been studied in clinical trials to treat COVID-19 in China.
</p>
